Yanxia Shi - Concepedia

Author

Yanxia Shi

Sun Yat-sen University ORCID

Also Known As

Kimberly H Allison, Shi, Y., Y Shi, Y X Shi, Y. Shi, YANXIA SHI, Yan-Xia Shi, Yan-xia Shi, Yanxia Shi, Yan‐Xia Shi

129

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Sun Yat-sen University Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Hunan Cancer Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

About

Yanxia Shi is an author at Sun Yat-sen University specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	816
2	Engineering	1	1	27
3	Health Sciences	1	1	79
4	Public Health	1	1	23
5	Biostatistics	1	1	27

Yanxia Shi

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression Guocan Wang, Xin Lü, Prasenjit Dey, Cancer Discovery	2015	536
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Xinan Sheng, Xieqiao Yan, Lin Wang, Clinical Cancer Research	2020	266
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial Yu‐Pei Chen, Xu Liu, Qin Zhou, The Lancet OncologyAdvanced Nasopharyngeal CarcinomaMetronomic TherapyNasopharyngeal CancerPathology	2021	217
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial Binghe Xu, Qingyuan Zhang, Pin Zhang, Nature Medicine Breast OncologyMedicinePharmacologyBreast CancerPharmacotherapy	2021	152
EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray Donggen Liu, Jiehua He, Zhongyu Yuan, Medical Oncology Breast OncologyOncologyEgfr Expression CorrelatesMedicinePathology	2011	104
The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer Xin An, Fei Xu, Rongzhen Luo, BMC Cancer	2018	82
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, The Lancet Oncology Breast OncologyHealth SciencesMedicinePharmacologyClinical Trials	2023	79
The CDK1 inhibitor RO3306 improves the response of BRCA-proficient breast cancer cells to PARP inhibition Qing Xia, Yuchen Cai, Roujun Peng, International Journal of Oncology Breast OncologyParp InhibitionMedicineImmune Checkpoint InhibitorBreast Cancer	2013	58
Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma Yonathan Lissanu Deribe, Yanxia Shi, Kunal Rai, Proceedings of the National Academy of Sciences	2016	56
An assessment of prognostic immunity markers in breast cancer Benlong Yang, J.-H Chou, Yaozhong Tao, npj Breast Cancer	2018	45

Page 1